Compared to the untreated controls, CD33+IL4Rα+MDSCs were significantly lower inside the tumor in the treated patients (Figure 5A), whereas no differences were found at the tumor edge or in the “normal” tissue nor in the total number of CD33+IL4Rα− myeloid cells (Figure 5B and Supplementary Figure 5). This evidence concerns the gene IL4R and neoplasm.